Special Issue

Recent Advances in Immunotherapy of Cancer

Message from the Guest Editors

Cancer immunotherapy has transformed cancer treatment by leveraging the immune system to identify and eradicate tumors. However, challenges such as treatment resistance, patient heterogeneity, and the increasing incidence of immune-related adverse events (irAEs) continue to pose significant obstacles. Incorporating artificial intelligence (AI) has transformative potential in addressing the challenges associated with cancer treatment. AI-driven approaches enhance precision medicine by optimizing patient selection, identifying biomarkers for treatment response and toxicity, and elucidating the complex dynamics of tumor–immune interactions. Additionally, AI facilitates early detection and management of immune-related adverse events (irAEs) by predicting at-risk patients and personalizing interventions. This Special Issue aims to highlight advancements in cancer immunotherapy, the management of irAEs, and the integration of AI to refine and personalize therapeutic strategies. We invite authors to submit papers on a variety of approaches to propel the field of immunotherapy toward safer, more effective, and tailored cancer treatments.

Guest Editors

Dr. Jessica Chacon
Texas Tech University Health Sciences Center, El Paso, TX, USA

Dr. Shrikanth Gadad
Texas Tech University Health Sciences Center, El Paso, TX, USA

Deadline for manuscript submissions

20 February 2026

Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed

About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès
Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi
Department of Emergency and Critical Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).